D. Haydar Laboratory
About the Lab
The D. Haydar Laboratory works on designing effective, long-lasting, and safe cellular immunotherapies for childhood brain cancer. CAR T cell therapy is an innovative technology based on adoptive transfer of antigen-specific T cells engineered to elicit a clinically effective and specific immune response against tumor cells. Our aim is to investigate mechanisms responsible for the lack of CAR T cell efficacy in pediatric brain tumors using cutting-edge technologies and innovative animal models that recapitulate human disease and barriers for adoptive immunotherapies.
Lab Focus Areas
Institute for Biomedical Sciences (IBS) Program, George Washington University School of Medicine and Health Sciences
Howard University Graduate School
cBAF complex components and MYC cooperate early in CD8+ T cell fateGuo, Ao, et al. Nature 607.7917:135-141 (2022)
T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic ChallengesHaydar, Dalia, et al. Frontiers in Oncology 11 (2021)
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell deliveryHaydar, Dalia, et al. Neuro-Oncology 23.6:999-1011 (2021)
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activityPrinzing, Brooke, et al. Science Translational Medicine 13.620:eabh0272 (2021)
Dalia Haydar, Pharm.D., Ph.D.
- Research Faculty
- Principal Investigator, Program for Cell Enhancement and Technologies for Immunotherapies (CETI)